X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The net proceeds will be used in the clinical development of CT1812, which is being evaluated in Phase II clinical trial studies for the treatment of Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 14, 2024
Details:
The net proceeds will be used in the clinical development of CT1812, which is being evaluated in Phase II clinical trial studies for the treatment of Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 11, 2024
Details:
CT1812 is an experimental orally delivered small molecule sigma-2 (σ-2) receptor modulator designed to penetrate the blood-retinal barrier and currently is in development for geographic atrophy secondary to dry age-related macular degeneration.
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and is currently in development for mild-to-moderate Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers and currently in development for mild-to-moderate Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institute on Aging
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2023
Details:
CT1812 binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes, that are damaged by toxic interaction with soluble beta amyloid oligomers, oxidative stress and other stressors. In dry AMD, this results in vision loss.
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
CT1812, binds selectively to the sigma-2 receptor complex which is involved in the regulation of key cellular processes that are damaged by toxic interaction with Aβ oligomers, oxidative stress, leading in cognitive impairment and alzheimer’s progression.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 22, 2023
Details:
CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex. It is being developed for cognitive impairment and alzheimer’s disease progression.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
CT1812 is an oral small molecule designed to penetrate the blood-brain barrier and bind selectively to the sigma-2 (σ-2) receptor complex. CT1812 is an experimental candidate and has not been approved by the U.S. FDA or other regulatory agency.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
CT1812 is an experimental oral sigma-2 (σ-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
The SHIMMER study is evaluating, Elayta (CT1812) in adults ages 50 to 85 who have been diagnosed with mild to moderate DLB. CT1812 is intended to enter the brain and block proteins (called amyloid beta oligomers and α-synuclein oligomers) from attaching to brain cells.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The funding aims to initiate the SEQUEL trial is to investigate whether treatment with CT1812 results in a normalization of the EEG patterns, as measured by quantitative electroencephalogram (qEEG).
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: CT1812
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2022
Details:
CT1812 has been well tolerated in clinical studies to date. Mild and transient elevations of liver enzymes without indication of liver injury have been recorded. No SAEs have been reported in patients treated with CT1812.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Elayta (CT1812) is an oral molecule that selectively binds to the sigma-2 receptor complex. Evidence implicates σ-2 receptors in the regulation of key cellular processes that are damaged in Alzheimer’s disease, dementia with Lewy bodies and other neurodegenerative disorders.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Elayta (CT1812) is a small-molecule antagonist of the sigma2 receptor. It binds to the progesterone receptor membrane component 1 subunit of the receptor complex.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Miami Miller School of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
Results presented at ARVO demonstrate that this vital function is rescued in vitro by addition of σ-2 receptor modulators including CT1812, Cognition’s lead clinical candidate for dry AMD, as well as σ-2 modulators from two distinct families of compounds in Cognition’s library.
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Preclinical results for CT1812, showed that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD).
Lead Product(s): CT1812
Therapeutic Area: Ophthalmology Product Name: CT1812
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
CT1812 is a brain-penetrant small molecule drug that binds to a receptor on neurons that regulates cellular damage response pathways, which are dysregulated in neurological diseases like Alzheimer’s disease.
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The funding is provided for over five years to support a 540-patient Phase 2 study of CT1812 in individuals with early Alzheimer’s disease. The study will be conducted in conjunction with the Alzheimer’s Clinical Trials Consortium (ACTC).
Lead Product(s): CT1812
Therapeutic Area: Neurology Product Name: Elayta
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $75.8 million Upfront Cash: Undisclosed
Deal Type: Funding June 09, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
